ACE and metabolic dysfunction-associated steatotic liver disease: Larger studies have shown similar favorable results in improving hepatic fibrosis, liver stiffness, and other markers of NAFLD after treatment with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) [152,153,154].